Table 2.

Principle safety and effectiveness data of the 2.25 mm taxus Liberté Atom stent in small vessels in the taxus ATLAS Small Vessel trial

Parameter	TAXUS ATLAS Small Vessel
	Case-matched (2.2–2.5 mm RVD) patients
	TAXUS Liberté Atom (n = 261)	TAXUS Express Atom (n = 75)	P-value
Angiographic follow-up47	9 Months
In-stent late loss, mm	0.28 ± 0.45	0.44 ± 0.61	0.03
In-stent binary restenosis	13.0%	25.9%	0.02
Clinical follow-up47	9 Months
TLR	5.8%	13.7%	0.02
TVR	10.1%	17.8%	0.07
MACE*	12.8%	20.5%	0.10
Cardiac death	0.8%	2.7%	0.46
ST#	0.4%	1.4%	0.39
Follow-up50	24 Months§
TLR	8.2%	20.3%	0.005
TVR	12.8%	26.1%	0.007
MACE	16.5%	30.4%	0.01
Cardiac death	2.1%	4.3%	0.38
ST#	0.8%	1.5%	0.52
Follow-up51	36 Months§
TLR	10.0%	22.1%	0.008
TVR	15.2%	27.9%	0.02
MACE*	19.5%	32.4%	0.03
Cardiac death	2.6%	4.4%	0.43
ST#	1.4%	1.5%	>0.99

Notes:

^*Includes cardiac death, myocardial infarction, and target vessel revascularization.

^#Academic Research Consortium definite/probable definition.

^§Consists of patients who received a study stent at baseline.

Abbreviations: TLR, target lesion revascularization; TVR, target vessel revascularization; MACE, major adverse cardiac event; ST, stent thrombosis.